Year: 2025
Type: article
Study design: Case Report
Abstract: BACKGROUND: Lecanemab is a disease-modifying immunotherapy for Alzheimer's disease (AD) and has been increasingly prescribed to the patients in the world. It has a definite therapeutic effect in slowing cognitive decline in AD patients, but its adverse drug reactions should not be ignored. CASE PRESENTATION: We reported an 82-year-old Chinese AD patient who developed recurrent D-dimer elevation after lecanemab infusions. His D-dimer levels were positively correlated with activated partial thromboplastin time, C-reactive protein, and neutrophil percentage, but negatively correlated with platelet count. CONCLUSIONS: Elevated D-dimer levels may be associated with the enhanced phagocytic response to vascular amyloid β upon lecanemab treatment. Our report expands knowledge on lecanemab's adverse drug reactions, suggesting that D-dimer levels and potential thromboembolic events should be monitored during treatment. CLINICAL TRIAL NUMBER: not applicable.
Source: BMC Geriatrics
Authors: Ming Zou, Shan-Shan Xu, Shi-Guo Zhu, Cheng-Xiang Yuan, Jie-Fan Huang, Jian-Hong Zhu, Xiong Zhang, Jian-Yong Wang
Language: English
Subfield: Physiology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,190
OpenAlex ID: W4414601580